Laggard turning growth stock

(Full access for Members only)

Laggard turning growth stock

Laggard turning growth stock

24 May 2024

The company featured in this report is highly cash-generative, debt-free, and has hundreds of millions of available cash sitting on its balance sheet.

It's Europe's market leader by some metrics.

With a EUR 1.5bn market cap, it's anything but a micro-cap.

Yet, it has a 3x-5x upside over the coming 3-5 years if new management gets its growth engines revved up again.

If the company's founder fails with his proxy battle to replace management, there'll probably be a bid for the company and a going-private at a price 25% above the current share price. It'd be the only logical conclusion.

This is an asymmetric opportunity, i.e. it seems to have limited downside but large upside.

Download report (PDF - 4.5MB)

Not a Member yet? Sign up for a Membership - just USD 49/year.
Already a Member? Log into your account to download the report.

Most recent

More Weekly Dispatches

Latest reports (for Members only)

2-2.5x from an investment holding liquidation

2-2.5x from an investment holding liquidation

This AIM-listed small-cap will likely return all its capital to shareholders. Underresearched by investors, it's an opportunity that shouldn't even exist – but it does.

Ukraine reconstruction: one stock to benefit

Ukraine reconstruction: one stock to benefit

If or when the war in Ukraine ends, this stock will likely become the focus of investor money pushing into the country.

Actinium-225, aka "the world's rarest drug"

Actinium-225, aka "the world's rarest drug"

This little-known Western European company could become the global market leader for supplying the uber-rare "Ac-225", a potent weapon to treat cancer.

All reports